Weekly Digest – May 2026 Weekly Digest – May 2026 06 May 2026: HLX43 received PMDA acknowledgment to initiate a global Phase 2/3 trial in squamous Non-Small Cell Lung Cancer Henlius has achieved a key milestone for its anti-PD-L1 ADC […]
Weekly Digest – April 2026 Weekly Digest – April 2026 30 March 2026: Zymeworks receives U.S. FDA Fast Track Designation for ZW191, an FRα-targeting ADC Zymeworks’ FRα-targeting ADC, ZW191, has received FDA Fast Track designation for patients with advanced or […]
Weekly Digest – April 2026 Weekly Digest – April 2026 01 April 2026: RemeGen’s dual-antibody ADC RC288 for the treatment of advanced malignant solid tumors has been officially approved for clinical trials RemeGen’s dual-target ADC, RC288, has received clinical trial […]
Weekly Digest – August 2024 Weekly Digest – August 2024 07 Aug 2024: Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors Exelixis has started the dose-escalation stage of a Phase […]
Weekly Digest – August 2024 Weekly Digest – August 2024 07 Aug 2024: Daiichi Sankyo and MSD expand collaboration on ADC development Daiichi Sankyo and MSD have expanded their partnership to globally develop and commercialize three DXd antibody-drug conjugates, including […]
Weekly Digest – August 2024 Weekly Digest – August 2024 07 Aug 2024: Exelixis drops tissue factor-targeting ADC after deciding it’s no match for Tivdak Exelixis has decided to discontinue development of its tissue factor-targeting antibody-drug conjugate, XB002, after assessing […]
Weekly Digest – August 2024 Weekly Digest – August 2024 05 Aug 2024: Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of JK06, a 5T4-Targeted ADC, in Solid Tumors Salubris Biotherapeutics has received EMA […]
